



Dr Muhammad Tani bin Tabiin has been the General Manager of A*STAR's (Agency for Science, Technology and Research, Singapore) spin-off company, Cellbae Pte Ltd since 2017 and its CEO since Jan 2020. He is responsible for managing the daily operations such as managing the development of Cellbae's product pipeline, sourcing for suppliers, regulatory approval strategy, pricing strategy, financial forecasting, input into marketing collaterals, intellectual property management, identifying and establishing distributors in over 20 countries as well as product launch.

Prior to Cellbae, Dr Tabiin was a General Manager at Vertex Ventures Pte Ltd, the venture capital arm of Temasek Holdings Pte Ltd and seconded to Temasek Lifesciences Accelerator Pte Ltd (TLA). He and his team managed the Accelerator which had 15 incubatees and successfully fundraised for TLA incubatees Hummingbird Biosciences, Allegro Aqua, Zero2.5 Biotech and Pathnova.

From 2015-2018, Dr Tabiin was the COO at miRNA diagnostics company, MiRXES Pte Ltd. He was in-charge of business development, collaborations, fundraising and intellectual property management for the NUS/A*STAR spin-off. He and his team successfully raised SGD4Mil for MiRXES' Series Seed and SGD40Mil for Series A, established distributors in more than 30 countries as well as led the company to obtain its CE mark and ISO 13485 certification for its gastric cancer diagnostic product.

Before joining MiRXES, Dr Tabiin worked his way up from Assistant Manager to Senior Vice President and the Head of the Biomedical Sciences Division (BMS), Accelerate Technologies Pte Ltd (ATPL), the strategic marketing and commercialisation arm of A*STAR during the 10+ years there.

As the Head of BMS for 7 years, Dr Tabiin led a team of 22 licensing professionals who were responsible for the commercialization of Biomedical technologies from the 20+ research institutes, consortiums and centres funded under A*STAR. The Biomedical Sciences Division in collaboration with other ATPL Divisions also provided technology management services such as intellectual property filing and management, technology and competitive intelligence, valuation, licensing, project management and spin-off company support to A*STAR research institutes.

Dr Tabiin and his team initiated, developed and managed initiatives to attract foreign direct investments to Singapore. They completed more than 100 early stage technology development projects with large pharma and biotech companies worth more than \$110 Mil with an 85% success rate. They spun off more than biomedical 35 start-up companies and closed more than 300 licenses to local SMEs as well as multinational companies worth several billion dollars.

Prior to joining ATPL, Dr Tabiin had a balanced career in academia as well as in the industry. He held research positions at the Joslin Diabetes Center, Harvard Medical School and the Genetic Immunotherapy Laboratory at Johns Hopkins. Before pursuing academic research, he held product development positions at Genelabs Diagnostics and Merck (EMD).